Contrary to previous theories suggesting that negative PSMA-expressing tumours are associated with neuroendocrine differentiation and worse prognosis, Veerman et al. results demonstrated these patients have similar clinical and pathological characteristics to patients with PSMA-expressing PCa, suggesting, in turn, that treatment for curative intent should not be withheld on these grounds [21,24]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.